CAR-T Cell Therapy
Phase 2Cell therapy
CAR-T Cell Therapy is one of 85 small molecule programs targeting Lymphoma. It is currently in Phase 2.
4
Indications
13
Total Trials
11
Active Trials
84
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
401 competitors in Lymphoma
#DrugCompanyPhaseTrials
1CAR-T Cell Therapy
TThe First Affiliated Hospital of Soochow University
Phase 2
Zofran
NovartisPreclinical
Cabenuva
GSKPreclinical
Norvir
AbbViePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma5 trials
CAR T Cell Therapy2 trials
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
Active, not recruiting·TThe First Affiliated Hospital of Soochow University·Phase 1/2·NCT03919240·196 enrolled
Relapsed/Refractory AML1 trial
Refractory1 trial
3 more indications
T Cells1 trial
Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL
Unknown status·—·Phase 1/2·NCT04206943·24 enrolled
Acute Lymphoblastic Leukaemia1 trial
Mantle Cell Lymphoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CAR-T Cell Therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details